First phase hepatitis c viral kinetics in previous nonresponders patients

Related Experiment Video

Updated: Aug 10, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

S J Cotler1, J E Layden, A U Neumann

  • 1Section of Hepatology, RUSH-Presbyterian-St. Luke's Medical Center; University of Illinois at Chicago, Chicago, IL 60612, USA. scotler@rush.edu

Journal of Viral Hepatitis
|February 1, 2003
PubMed

Insights

Higher interferon doses improve hepatitis C treatment response in nonresponders. This study shows increased viral load reduction with 30 mcg of interferon alfacon-1 in nonresponder patients compared to lower doses.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Many patients do not respond to hepatitis C treatment.
  • Interferon therapy initially reduces viral load by inhibiting production or release.
  • Understanding viral kinetics in nonresponders is crucial for optimizing treatment.

Purpose of the Study:

  • To characterize first-phase viral kinetics in hepatitis C nonresponders.
  • To compare the antiviral efficacy of interferon alfacon-1 in nonresponders versus naive patients.
  • To evaluate the impact of different interferon alfacon-1 doses on viral load reduction.

Main Methods:

  • Twenty nonresponder patients with genotype 1 hepatitis C received 15 mcg or 30 mcg of interferon alfacon-1.
  • Viral kinetic data were compared to historical controls of naive patients receiving 9 mcg or 15 mcg.
  • Antiviral efficacy was measured by log reduction in HCV RNA levels within 24 hours (log effectiveness).

Main Results:

  • Hepatitis C virus levels decreased exponentially in nonresponders.
  • A 30 mcg dose of interferon alfacon-1 showed significantly greater viral load reduction than a 15 mcg dose in nonresponders (P=0.01).
  • Higher doses of interferon alfacon-1 in nonresponders achieved comparable or superior log effectiveness to doses used in naive patients.

Conclusions:

  • Interferon's antiviral effectiveness is generally lower in nonresponders compared to naive patients.
  • Higher doses of interferon alfacon-1 can overcome the reduced effectiveness in previous nonresponders.
  • Prior partial response to treatment may predict a greater viral load reduction with subsequent interferon therapy.

More Related Videos

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...